The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
A pregnant woman and a man suffered "severe discomfort" after someone threw bleach at them from a passing car, hitting them in the eyes.
A look at the weather today across the UK.
Former child star Erin Moran who played Joanie Cunningham in the US sitcom "Happy Days" has been found dead at 56.